Prime Medicine (PRME) Research & Development (2021 - 2026)

Prime Medicine (PRME) has 6 years of Research & Development data on file, last reported at $34.1 million in Q1 2026.

• Quarterly Research & Development fell 15.92% year-over-year to $34.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $154.2 million (down 2.47% YoY) and the FY2025 annual result came in at $160.6 million, up 3.44% from the prior year.
• Research & Development slipped to $34.1 million in Q1 2026, from $34.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $44.0 million in Q3 2025 to a low of $13.7 million in Q1 2022.
• A 5-year average of $34.4 million and a median of $34.7 million in 2025 frame the typical range for Research & Development.
• The widest YoY moves for Research & Development: up 238.47% in 2022, down 45.05% in 2022.
• Tracing PRME's Research & Development over 5 years: stood at $29.1 million in 2022, then jumped by 42.66% to $41.5 million in 2023, then dropped by 17.74% to $34.1 million in 2024, then increased by 1.77% to $34.7 million in 2025, then dropped by 1.74% to $34.1 million in 2026.
• The last three Research & Development figures came in at $34.1 million (Q1 2026), $34.7 million (Q4 2025), and $44.0 million (Q3 2025), per Business Quant data.